Upgrading Your Aggregate Analysis of Viral Vectors With Novel Wide Pore SEC Columns

Learn how novel wide pore size exclusion columns save you time and sample for critical quality attribute analysis of viral vectors such as AAVs and VLPs. See the high-resolution separations possible with the right pore and particle size, and chemistry.

Register Free: https://www.chromatographyonline.com/ca_w/upgrading

Event Overview:

Adeno-associated viruses (AAVs), virus-like particles (VLPs), oligonucleotides, and lipid nanoparticles represent the next generation of biotherapeutics for cell and gene therapy, as well as vaccines. Characterizing these novel and challenging biotherapeutics requires advanced, capable, and robust technology. Novel 500 and 1000 Å pore sizes provide suitability for samples of larger diameter, making them ideal for your aggregation analyses of ultralarge biomolecules (>1 MDa) such as AAVs and VLPs. Learn more about the reproducible, high-resolution separations possible with these robust new columns – and the time and cost savings that follow.

Key Learning Objectives:

• Learn how to adapt your protein size-exclusion chromatography (SEC) method for larger biotherapeutics
• Discover the robust reproducibility of novel ultrawide pore SEC columns
• Learn how to improve your critical quality attribute (CQA) analysis or viral vector such as AAVs
  

Who Should Attend:

Scientists and Researchers in

• CRO/CMO
• QA/QC
• R&D

Speakers:

Anne Blackwell, PhD
Product Manager
Agilent Technologies

Anne Blackwell, PhD, completed her degree in analytical chemistry at the University of Arizona in 2012. She focused on mass spectrometry of noncovalent proteins. Upon joining Agilent Technologies, she worked as an LC/MS applications chemist and then became a product support scientist for bio LC columns. Blackwell specialized in helping customers develop robust separations, implement best practices, and troubleshoot challenging problems prior to transitioning to product management.

Andrew Coffey, PhD
Senior Application Scientist
Agilent Technologies

Andrew Coffey, PhD, joined the biocolumns applications team at Agilent Technologies in 2011. He has over 34 years of experience in method development, technical support, and troubleshooting of reversed phase, ion exchange, size exclusion, and many other liquid chromatographic techniques.

Register Free: https://www.chromatographyonline.com/ca_w/upgrading